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Randomized, controlled trial evaluating the effect of multi-strain probiotic
on the mucosal microbiota in canine idiopathic inflammatory bowel
disease
Abstract
The intestinal microbiota is increasingly linked to the pathogenesis of idiopathic inflammatory bowel disease
(IBD) in dogs. While studies have reported alterations in fecal (luminal) microbial populations, only limited
information is available about the mucosal microbiota of IBD dogs at diagnosis and following medical therapy.
Our aim was to characterize the mucosal microbiota and determine the clinical, microbiological, and mucosal
homeostatic effects of probiotic treatment in dogs with IBD. Thirty four IBD dogs were randomized to receive
standard therapy (ST = diet + prednisone) with or without probiotic. Tissue sections from endoscopic
biopsies were evaluated by fluorescence in situ hybridization (FISH) on a quantifiable basis. Disease activity
and changes in mucosal microbiota and tight junction protein (TJP) expression were assessed before and after
8 weeks of IBD therapy. ST and ST/probiotic therapy modulated the number of mucosal bacteria of IBD dogs
in a similar fashion. Both treatments increased the numbers of total bacteria and individual species residing
within adherent mucus, with ST therapy increasing Bifidobacterium spp. and ST/probiotic therapy increasing
Lactobacillus spp (P < 0.05 for both), respectively. Both treatments were associated with rapid clinical
remission but not improvement in histopathologic inflammation. Probiotic therapy was associated with
upregulated (P < 0.05) expression of TJPs E-cadherin, occludin, and zonulin versus ST. The probiotic effect
on mucosal bacteria is similar to that of IBD dogs receiving ST. IBD dogs fed probiotic had increased TJP
expression suggesting that probiotic may have beneficial effects on mucosal homeostasis.
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ABSTRACT
The intestinal microbiota is increasingly linked to the pathogenesis of idiopathic inﬂammatory
bowel disease (IBD) in dogs. While studies have reported alterations in fecal (luminal) microbial
populations, only limited information is available about the mucosal microbiota of IBD dogs at
diagnosis and following medical therapy. Our aim was to characterize the mucosal microbiota and
determine the clinical, microbiological, and mucosal homeostatic effects of probiotic treatment in
dogs with IBD. Thirty four IBD dogs were randomized to receive standard therapy (ST D diet C
prednisone) with or without probiotic. Tissue sections from endoscopic biopsies were evaluated by
ﬂuorescence in situ hybridization (FISH) on a quantiﬁable basis. Disease activity and changes in
mucosal microbiota and tight junction protein (TJP) expression were assessed before and after
8 weeks of IBD therapy. ST and ST/probiotic therapy modulated the number of mucosal bacteria of
IBD dogs in a similar fashion. Both treatments increased the numbers of total bacteria and
individual species residing within adherent mucus, with ST therapy increasing Biﬁdobacterium spp.
and ST/probiotic therapy increasing Lactobacillus spp (P < 0.05 for both), respectively. Both
treatments were associated with rapid clinical remission but not improvement in histopathologic
inﬂammation. Probiotic therapy was associated with upregulated (P < 0.05) expression of TJPs
E-cadherin, occludin, and zonulin versus ST. The probiotic effect on mucosal bacteria is similar to
that of IBD dogs receiving ST. IBD dogs fed probiotic had increased TJP expression suggesting that
probiotic may have beneﬁcial effects on mucosal homeostasis.
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Canine idiopathic inﬂammatory bowel disease
(IBD) is a chronic, immunologically-mediated
enteropathy that is poorly understood.1,2 Data from
humans and animal models of intestinal inﬂamma-
tion indicate that deleterious host-microbiome
interactions can incite and perpetuate mucosal
inﬂammation. For example, genetic defects in
innate immune sensing and enteric bacterial killing
confer increased susceptibility to IBD in German
shepherd dogs (GSD) associated with a distinct
intestinal dysbiosis.3 Moreover, bacteria that adhere
and invade the intestinal mucosa, including strains
of Escherichia coli (E. coli), may be particularly
important for IBD pathogenesis in both humans4
and companion animals.5
Many studies have reported microbial imbalances in
canine IBD, characterized by a decrease in diversity, a
decreased abundance of some commensal members
(such as Clostridium clusters XIVa and IV), and an
increase in detrimental bacteria (such as and E. coli
and Enterobacteriaceae).6-8 While these earlier studies
have primarily reported changes in fecal microbial
populations, only limited information is available about
the mucosal microbiota present in dogs with IBD.
Gut microbiota modulation to correct microbial
perturbations might be obtained by several therapeutic
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Ames, Iowa 50011, USA.
Supplemental data for this article can be accessed on the publisher’s website.
© 2017 Taylor & Francis
GUT MICROBES
2017, VOL. 8, NO. 5, 451–466
https://doi.org/10.1080/19490976.2017.1334754
approaches, including diet, antibiotics, and probiotic
supplementation. Probiotics contain live, beneﬁcial
bacteria in sufﬁcient amounts to reach the intestine in
an active state and exert positive health effects.9 There
is only one investigation reporting on the efﬁcacy of
multi-strain probiotic therapy for canine IBD.10 This
earlier study included a small number of patients and
reported changes in the fecal, but not the mucosal,
microbiota following probiotic administration.
The aim of the present study was to compare the
effect of standard IBD therapy (ie, elimination diet
and oral prednisone) vs. standard therapy plus multi-
strain probiotic on the composition and spatial distri-
bution of the mucosal microbiota in dogs with idio-
pathic IBD.
Materials and methods
Ethics statement
Approval to conduct the study was obtained from the
Iowa State University (ISU) Institutional Animal Care
and Use Committee (IACUC log # 9–14–7859-K). All
clients provided informed written consent permitting
enrollment of their animal into the IBD clinical trial.
Animals and inclusion/exclusion criteria
Idiopathic IBD was diagnosed in 34 dogs based on the
following criteria: (1) history of persistent or intermit-
tent gastrointestinal (GI) signs of at least 3 weeks dura-
tion, (2) exclusion of identiﬁable underlying disorders,
(3) failed response to empiric (parasiticides, diet, anti-
biotics) therapies, and (4) histopathologic evidence of
GI mucosal inﬂammation.11 The minimum diagnostic
evaluation performed in all dogs included a complete
blood count (CBC), serum biochemistry panel, urinal-
ysis, GI panel to Texas A&M University (ie, trypsin-
like immunoreactivity [cTLI], canine pancreatic lipase
immunoreactivity [cPLI], and serum cobalamin/folate
concentrations), direct (wet mount)/indirect (zinc sul-
fate ﬂotation) examination of feces for nematode and
protozoan parasites, resting cortisol/ACTH stimulation
test, abdominal radiographs, and histopathologic
review of endoscopically-derived biopsy specimens.
Abdominal ultrasonography was performed in most
dogs (n D 25) at the clinician’s discretion.
Prior to trial enrollment, IBD suspect dogs had
been treated with an elimination (ie, intact protein or
protein hydrolysate) diet fed exclusively for at least
3 weeks followed by treatment with metronidazole
(10 mg/kg PO q12h for 3 weeks) and had failed to
respond to either therapy. All medications were with-
drawn at least 2 weeks before tissue collection. Clinical
disease severity was assessed using the canine IBD
activity index (CIBDAI) at all visits.12
Exclusion criteria included dogs with other causes
for GI signs besides idiopathic IBD, and treatment
with antimicrobials, anti-inﬂammatory drugs or both
within 14 d of presentation.
Study design
There were 3 study centers for case recruitment: Iowa
State University CVM, Colorado State University
CVM, and Veterinary Specialty Hospital – San Diego.
Following diagnosis of IBD, dogs were randomized by
means of a computer-generated schedule to receive
standard IBD therapy (deﬁned as an elimination diet
fed exclusively for the duration of trial and prednisone
PO at a dosage of 0.5–1 mg/kg q12h £ 3 weeks then
0.5 mg/kg q12h £ 3 weeks then maintained or tapered
over the 8 week duration of the study D ST), or stan-
dard therapy with a multi-strain probiotic (e.g.,
VisbiomeTM which contains the same strains, in the
same concentration and proportions, and is therapeu-
tically equivalent to the VSL#3 brand probiotic blend
as produced before January 31, 2016 D ST/probiotic).
The product contains the following strains: Lactobacil-
lus plantarum DSM 24730, Streptococcus thermophilus
DSM 24731, Biﬁdobacterium breve DSM 24732,
Lactobacillus paracasei DSM 24733, Lactobacillus
delbrueckii subsp. bulgaricus DSM 24734, Lactobacil-
lus acidophilus DSM 24735, Biﬁdobacterium longum
DSM 24736, and Biﬁdobacterium infantis DSM 24737
in the speciﬁc combination which is currently sold
under the brand Vivomixx in Continental Europe
and Visbiome in the USA and Canada. The percent-
age in weight of the various ingredients was: S.
thermopilus 40.55%, Biﬁdobacteria 12.5%, Lactobacilli
13%, and other excipients 39.05%. Dosing of the pro-
biotic (112–225 £ 109 CFU/10 kg; gift of Professor
Claudio De Simone) was based on enrollment body
weight and was administered using previously pub-
lished guidelines for treatment of canine IBD.10 In
brief, dogs weighing 10–20 kg body weight and ran-
domized to receive probiotic were administered cap-
sules containing 450 billion probiotic bacteria daily.
Dogs randomized to receive ST were administered a
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placebo consisting of an identical capsule that con-
tained maltodextrin. The probiotic and placebo capsu-
les were mailed from the GI Laboratory at Texas
A&M University directly to the client. Both the veteri-
nary gastroenterologist and client were blinded as to
whether the dog received probiotic or placebo as a
component of their IBD therapy.
Dogs were evaluated at study centers on 3 separate
visits: visit 1 (recruitment), visit 2 (» 3 weeks after
starting trial medications), and visit 3 (» 8 weeks after
starting trial medications; Fig. 1). The diagnostic pro-
cedures performed on dogs at each visit are listed in
Table 1. The ﬁnal on-site examination (visit 3 at
8 weeks) was performed while dogs were still receiving
trial medications.
Intestinal biopsy and histopathologic examination
Most dogs had diagnostic GI endoscopy performed for
the collection of duodenal, ileal and/or colonic biopsy
specimens. In some dogs with large bowel GI signs
alone, only colonic mucosal biopsies were obtained
for analysis. Dogs were prepared for colonoscopy
(visit 1) by withholding food overnight and adminis-
tering an oral colonic electrolyte lavage solution, twice,
at a dosage of 20 ml/kg. One or 2 tepid water enemas
(20 ml/kg) were performed in the morning before
endoscopic examination. Repeat colonoscopy (visit 3)
was performed without colonic cleansing by digital
evacuation of feces with collection of distal large bowel
biopsies from relatively fecal-free areas of colonic
mucosa. Prior to endoscopy, the endoscope and
biopsy forceps were thoroughly cleaned and sterilized
using an activated aldehyde solution and gas steriliza-
tion, respectively. Multiple (10–15 tissues from the
duodenum; 9–12 tissues from the colon; 3–6 tissues
from the ileum) endoscopic biopsies were obtained
and ﬁxed in 10% neutral buffered formalin and then
parafﬁn embedded for use in histopathology, using
H&E and immunohistochemical (IHC) stains, and for
FISH analysis.
Histopathologic examination of endoscopic paraf-
ﬁn-embedded tissue sections was performed by a sin-
gle pathologist (MA) blinded as to each dog’s history
and clinical course. Tissues were graded for severity of
intestinal mucosal inﬂammation using simpliﬁed
WSAVA histopathologic criteria.13
Fecal microbiota composition
To evaluate speciﬁc bacterial groups of interest to
intestinal health (e.g., Lactobacillus, Biﬁdobacterium,
Faecalibacterium, and Streptococcus genera present in
the probiotic cocktail) and bacterial species with
potential pathogenic roles (e.g., Escherichia coli, and
Clostridium perfringens) quantitative polymerase
chain reaction techniques (qPCR) were used as
described previously.14 One hundred mg of feces were
aliquoted into a sterile 1.7 ml tube (Microtube, Sar-
stedt AG & Co, N€umbrecht, Germany) containing
150 ml of 0.1 mm zirconia-silica beads and 100 ml of
0.5 mm zirconia-silica beads (BioSpec Products Inc.,
Barlesville, OK, USA). Samples were then homoge-
nized (FastPrep-24, MP Biomedicals, USA) for a dura-
tion of 1 minute at a speed of 4 m/s. DNA was then
extracted with the ZR fecal DNA Mini Prep kit follow-
ing the manufacturer’s instructions (Zymo Research,
Irvine CA, USA). Brieﬂy, qPCR reactions were per-
formed using 2 reaction chemistries. For a subset of
assays SYBR-green based reaction mixtures were used,
with a total reaction volume of 10 ml. The ﬁnal mix
contained 5 ml SsoFastTM EvaGreen supermix (Bio-
Rad Laboratories, CA, USA), 0.4 ml each of a forward
and reverse primer (ﬁnal concentration: 400 nM),
Figure 1. Trial design and ﬂow of IBD dogs. ST D standard
therapy.
Figure 2. Dog enrollment and disposition.
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2.6 ml of high quality PCR water, and 2 ml of normal-
ized DNA (ﬁnal concentration: 5 ng/ml). Conditions
for PCR were as follows: initial denaturation at 98C
for 2 min, then 40 cycles with denaturation at 98C
for 3 sec and annealing for 3 sec. Post-ampliﬁcation, a
melt curve analysis was performed using these condi-
tions: 95C for 1 min, 55C for 1 min, and increasing
incremental steps of 0.5C for 80 cycles for 5 sec each.
All samples were run in duplicate fashion. TaqMan
based reaction mixtures were used in a total reaction
volume of 10 ml. The ﬁnal mix contained 5 ml
TaqMan Fast Universal PCR master mix (Life Tech-
nologies, NY, USA), 0.4 ml of a forward and reverse
primer (ﬁnal concentration: 400 nM), 2 ml of high
quality PCR water, and 2 ml of normalized DNA (ﬁnal
concentration: 5 ng/ml). Conditions for PCR were as
follows: initial denaturation at 95C for 20 sec then 40
cycles with denaturation at 95C and annealing for
3 sec. Post-ampliﬁcation, a melt curve analysis was
performed using these conditions: 95C for 1 min,
55C for 1 min, and increasing incremental steps of
0.5C for 80 cycles for 5 sec each. A complete list of
primers and probes used in this study have previously
been published.10 All samples were run in duplicate
fashion. The qPCR data was expressed as log amount
of DNA (fg) for each individual bacterial group per
10 ng of isolated total DNA.
Fluorescence in situ hybridization (FISH)
The formalin-ﬁxed embedded histopathological tissue
sections were mounted on glass slides and evaluated by
ﬂuorescence in situ hybridization (FISH) as described
previously.15-17 In brief, parafﬁn-embedded tissue speci-
mens were deparafﬁnized using an automated system by
passage through xylene (3£ 10 min), 100% alcohol (2£
5 min), 95% ethanol (5 min), and ﬁnally 70% ethanol
(5 min). The slides were next rapidly transported in
deionized water to the DNA testing laboratory where
they were air-dried before hybridization. FISH probes 50-
labeled with either Cy-3 or FITC (Life Sciences) were
reconstituted with DNAse-free water and diluted to a
working concentration of 5 ng/mL (Table 2).
For total bacterial counts EUB338-FITC was
used. For other analyses, speciﬁc probes targeting
Biﬁdobacteria, Streptococci, Faecalibacteria, Lacto-
bacilli, and Enterobacteriaceae were labeled with
Cy-3 and were applied simultaneously with the
universal bacterial probe Eub338-FITC. This probe
array was selected to identify speciﬁc bacterial
groups and individual bacterial species previously
shown to be relevant in the pathogenesis of IBD in
humans and animals.18-22 Tissue sections were
bathed in 30 mL of DNA–probe mix in a hybrid-
ization chamber maintained at 54 C overnight
(12 h). Washing was performed using a wash
buffer (hybridization buffer without SDS), the slides
were rinsed with sterile water, then allowed to air-
dry, and mounted with SlowFade Gold mounting
media (Life Technologies, Carlsbad, CA) and 25 £
25–1 cover glass (Fisher Scientiﬁc, Pittsburgh, PA).
Probe speciﬁcity was conﬁrmed in pilot studies by
combining the irrelevant probe non-Eub338-FITC
with Eub338-Cy-3, and through hybridization
Table 1. Diagnostic procedures performed during trial visits. CIBDAI D canine IBD activity index; CBC/BC/UA D complete blood count,
biochemistry proﬁle, urinalysis; TLI/cPLI D trypsin like immunoreactivity and canine pancreatic lipase immunoreactivity.
Visit
History/Physical
examination CIBDAI CBC/BC/UA TLI/cPLI Folate/cobalamin
Cortisol or ACTH
stiumulation
Fecal
examination
Endoscopy
with biopsy
V1 X X X X X X X X
V2 X X As needed
V3 X X As needed X
Table 2. Probes used for ﬂuorescence in situ hybridization.
Probe Sequence (50 ! 30) Target Reference
Eub338 GCT GCC TCC CGT AGG AGT Bacteria Amann (1990)
Bif164 CAT CCG GCA TTA CCA CCC Biﬁdobacterium spp. Harmsen (2000)
Ebac1790 CGT GTT TGC ACA GTG CTG Enterobacteriaceae Poulsen (1994)
Faecali698 GTG CCC AGT AGG CCG CCT TC Faecalibacterium spp. Garcia-Mazcorro
(2012)
Lab158 GGT ATT AGC ATC TGT TTC CA Lactobacillus spp. Harmsen (2000)
Strc493 GTT AGC CGT CCC TTT CTG G Streptococcus spp. Franks (1998)
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experiments with pure bacterial isolates to screen for
non-selective hybridization.
In situ quantiﬁcation of mucosal bacteria
The bacteria were visualized by FISH and 4,6-diami-
dino-2-phenylindole (DAPI) staining using a 60x Plan
Apo oil objective in conjunction with an optional 1.5x
multiplier lens on an Eclipse TE2000-E ﬂuorescence
microscope (Nikon Instruments Inc., Melville NY)
and photographed with a CoolSnap EZ camera (Pho-
tometrics, Tuscon, AZ) controlled by MetaMorph
software (Nashville, TN). Quantiﬁcation was only per-
formed when the hybridization signals were strong
and could clearly distinguish intact bacteria morpho-
logically by either 2-color (universal and bacterial spe-
ciﬁc FISH probe) or 3-color (FISH probes and DAPI
stain) identiﬁcation. A minimum of 4 different endo-
scopic biopsy specimens/organs were evaluated for
their mucosal bacterial content. Bacterial quantiﬁca-
tion was performed in 10 representative ﬁelds at a
ﬁnal observed magniﬁcation of 600x or 900x. Each
counting ﬁeld generally included bacteria found
within mucosal and adjacent supra-mucosal regions.
The 10 ﬁelds included bacteria located within 4 well-
deﬁned mucosal compartments: (1) bacteria contained
within the mucosa, (2) bacteria attached to the surface
epithelium, (3) bacteria localized within adherent
mucus, and (4) bacteria found within free mucus
(Supplemental Fig. 1).23 The number of bacteria per
compartment summed across the 10 counting ﬁelds
for each probe in each dog was used in statistical
analysis.
Immunohistochemistry for tight junction protein
expression
Parafﬁn tissue sections were rehydrated and neutralized
for endogenous peroxidases using 3% hydrogen peroxide
for 5 minutes then rinsed for 5 minutes in distilled water.
For antigen retrieval, slides were incubated in an antigen
retrieval solution of 0.01 M Tris-EDTA buffer (pH9.0)
for claudin 2, occludin and E-cadherin in a steamer
(Black & Decker, Towson, MD, USA) for 20 minutes.
For zonulin stain, slides were immersed in a staining dish
containing Sodium Citrate Buffer (10mM Sodium Cit-
rate, 0.05% Tween 20, pH 6.0) which was heated to
95–100C in a water bath and with the lid placed loosely
on the staining dish for an optimal incubation of
35 minutes. Following incubation, the slides were cooled
for 20 minutes then washed in PBS-Tween 20 for 2 £
2 minutes. For all tissue sections, non-speciﬁc binding
was blocked by incubation with a protein-blocking agent
(Protein-blocking agent, Dako, Carpinteria, CA, USA)
for 10minutes before application of the primary antibod-
ies. Slides were incubated overnight in a moist-chamber
(4C) with the following primary antibodies: Polyclonal
rabbit anti-claudin-2 (Polyclonal rabbit anti-claudin-2
(PAD: MH44), Invitrogen Ltd., Paisley, UK)and anti-
occludin (anti-occludin PAD: Z-T22, Invitrogen Ltd.,
Paisley, UK) antibodies and monoclonal mouse anti-E-
cadherin IgG2a (Monoclonal mouse anti-E-cadherin
IgG2a (clone: 36), BD Biosciences, Oxford, UK) as
described previously.10 For zonulin stain, the primary
antibody was a rabbit derived polyclonal antibody (anti-
Zonulin pAb, LS-C132998, LSBio Inc., USA, diluted
1:300). The immunohistochemistry stain LS-C132998
pAb was validated previously using a panel of 21 forma-
lin-ﬁxed, parafﬁn-embedded (FFPE) human and canine
tissues after heat-induced antigen retrieval in pH 6.0 cit-
rate buffer. Following incubation with the primary anti-
bodies, slides were incubated with biotinylated secondary
antibodies. These antibodies included 1) goat anti-rabbit
biotinylated immunoglobulin (E0432, Dako, Glostrup,
Denmark) used at a dilution of 1:250 and incubated for
1 hour to bind polyclonal rabbit-derived anti-zonulin,
claudin-2 and occludin antibodies; and 2) goat polyclonal
anti-mouse biotin-coupled secondary antibody (E 0443,
Dako, Glostrup, Denmark) used at dilution of 1:200 and
incubated for 1 hour to bindmonoclonal murine-derived
anti-E-cadherin antibody. The incubation with second-
ary antibodies was followed by an avidine-biotin complex
(ABC elite, Vector, Burlingame, UK) incubation of
Table 3. Baseline parameters of IBD dogs completing the treat-
ment trial. CIBDAI D canine IBD activity index; ST D standard
therapy. aMean disease activity at diagnosis, range 0–18. bMu-
cosal lesions of increased granularity, friability, and/or erosions
visualized. cHistopathologic severity of mucosal inﬂammation.
Parameter
ST Group
(nD12)
ST/probiotic
Group (nD14)
Mean age (yr.) 6.2 4.6
Range (1.5-10) (1-8)
Mean weight (kg.) 26.7 18.8
Range (6.3-47.3) (5-34.1)
Male sex, n (%) 7 (58) 8 (57)
Disease duration (mo.) 10.5 7.3
CIBDAI scorea 8.1 6.7
Endoscopic lesionsb 100% 100%
Histopathologic gradec
Mild IBD 37% 40%
Moderate-severe IBD 63% 60%
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45 minutes and a chromogen (DAB and Vector VIP,
Vector) incubation generally of 10 minutes, but under
directmicroscope-control, evaluating the degree of inten-
sity of the stain.
To assess expression of claudin-2, occludin, E-cad-
herin, and zonulin proteins in endoscopic biopsies
obtained before and after either treatment, stained tissue
sections were evaluated at £ 200 and £ 630 (oil immer-
sion) magniﬁcation to identify areas of consistent stain-
ing and acceptable orientation. Immunostaining was
evaluated along the length of multiple enteric/colonic
crypts and in areas of intact luminal epithelium. Stain
intensity was subjectively graded as absent (¡), weak
(C), moderate (CC), or strong (CCC), and the localiza-
tion and distribution of chromogen within cells were
noted. For quantiﬁcation of the number of TJP express-
ing cells, the intestinal epithelium was divided into lumi-
nal, proximal, and distal gland/crypt regions, and the
intercellular junction was divided into apical and basolat-
eral compartments. All IHC positive cells were quantiﬁed
using a light microscope (Carl Zeiss), a £ 40 objective, a
£ 10 eyepiece, and a square eyepiece graticule (10 £ 10
squares, with a total area of 62,500 mm2). Ten appropri-
ate sites were chosen for each compartment and arithme-
tic means were calculated for each intestinal region.
Results were expressed as the number of IHC positive
cells per 62,500mm,2 regardless of staining intensity. The
IHC stained slides were evaluated in a blinded manner
by a single pathologist (GR) to conﬁrm staining speciﬁc-
ity and to perform quantiﬁcation of the number of TJP
expressing cells.
Outcome measures
The primary endpoints were changes inmucosal bacteria,
induction of clinical remission, and immunohistochemi-
cal evaluation of tight junction protein expression in
intestinal biopsies. Clinical remission was deﬁned as a
decrease in the CIBDAI of 50% or more from baseline
(week 0) to visit 2, and a decrease in the CIBDAI of 75%
ormore from baseline to visit 3.11
Secondary measures included total histopathologic
score pre- vs. post-therapy, fecal microbiota composition,
the need for pharmacologic treatments outside the study
regimen, and any adverse drug or probiotic reactions.
Statistical analysis
Tabular data were organized by mucosal compartment
and treatment group of dogs. Mean, median,
minimum, and maximum values were calculated from
the bacterial counts. Median values were compared
among groups using the Wilcoxon rank sum tests.
Similar summary statistics were performed on cells
expressing individual TJPs with median values com-
pared between the duodenum and colon before and
after treatment using Wilcoxon rank sum tests. Asso-
ciations between bacterial numbers and histopatho-
logic score were assessed using linear mixed models
with dogs as a random effect. Histopathologic scores
were compared between dog groups over time using a
one way ANOVA and student’s T test. Association
among other variables were assessed using Spearman’s
rank correlation and tested for signiﬁcance.
For statistical comparisons of temporal qPCR data,
differences between time points were evaluated within
either the ST or ST/probiotic group. Log DNAwas tested
for normality using the Shapiro-Wilk test and the normal
assumption was rejected for most data sets. Therefore, a
Friedman’s test was used to evaluate repeated measures
within either of the IBD treatment groups.
A Dunn’s post-test was then used where Friedman’s
test was found to be signiﬁcant. For the qPCR data analy-
ses, 9 dogs were evaluated in the ST group while 10 dogs
were evaluated in the ST/probiotic group. The level of sig-
niﬁcance for all comparisons was set at P< 0.05.
Sample size for enrollment was calculated following
consultation with a statistician (n D 32 total dogs over
36 months which included a 20% “washout”) and was
based on initial power calculations using variability in
CIBDAI scores between IBD treatments.11 Randomi-
zation of 16 dogs per group would give a power of
80% to detect this difference at the 0.05 signiﬁcance
level. Additional dogs were enrolled to allow for a
noncompliance rate up to 20%.
Results
Trial enrollment and completion
Thirty four dogs were enrolled in the trial with 17
dogs assigned to the ST group and 17 dogs assigned to
the ST/probiotic group (Fig.2). No dog was withdrawn
before treatment assignment. Five dogs in the ST
group did not complete the trial. One dog was with-
drawn because of severe refractory GI disease associ-
ated with protein-losing enteropathy (PLE) and was
killed. A second dog never returned after enrollment
and was lost to follow-up. Three other dogs were
excluded following diagnosis of alimentary neoplasia
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(2 dogs with small intestinal lymphoma [LSA] and
one dog with colonic adenocarcinoma) on repeat
endoscopy at visit 3.
In the ST/probiotic group, 3 dogs failed to complete
the trial due to possible adverse medication(s) reaction
(n D 1), severe refractory GI disease requiring antibi-
otics (n D 1), and small intestinal LSA diagnosed on
visit 3 repeat endoscopy with histopathology.
Ultimately, 12 dogs in the ST group and 14 dogs in
the ST/probiotic group completed the 8 week clinical
trial.
There was no signiﬁcant difference in total histopatho-
logic scores between treatment groups at visit 1. Both dog
groups combined (e.g., 69% of total dogs) were diagnosed
with moderate-to-severe intestinal inﬂammation charac-
terized by a predominant lymphocytic-plasmacytic inﬁl-
trate which was variably increased within the intestinal
lamina propria. Post-treatment histology scores (visit 3)
failed to differ signiﬁcantly between treatment groups
nor to improve signiﬁcantly with either therapy as com-
pared with visit 1.
There were 2 dogs that required drug therapy outside
the study regimen. One dog (ST/probiotic cohort) with
PLE and steroid refractory disease was placed on cyclo-
sporine (5mg/kg PO q24h) from visit 2 to visit 3; a sec-
ond dog (ST cohort) developed a bacterial urinary tract
infection (UTI) at visit 2 and was placed on
systemic antibiotics. Following urine culture conﬁrma-
tion of infection, treatment with placebo was stopped,
the dog was administered a penicillin plus clavulanic
acid antibiotic for 14 days, and repeat urinalysis/urine
culture was performed to conﬁrm eradication of the bac-
terial UTI. Following a 2 week washout period where the
dog was maintained only on the elimination diet and
prednisone (0.25 mg/kg PO q 12h), the dog was placed
back on placebo for the remaining 5 weeks of the trial.
No major adverse effects were reported. Two dogs
in the ST/probiotic arm had soft stools during the ﬁrst
week of therapy; one other dog in the same group had
increased vomiting during week 2 of therapy and
withdrew from the study. In each instance, it could
not be determined whether GI signs were attributable
to the medical intervention or underlying IBD activity
(e.g., disease ﬂare).
Baseline clinical data
The majority (24/26, 92%) of dogs completing the trial
had clinical signs of enteritis or enterocolitis; 2 dogs
were enrolled with signs of large bowel diarrhea alone.
Dogs in both groups comprised a diverse mix of pre-
dominantly pure breed dogs with German shepherd
dogs, Labrador retrievers, Beagles, Welsh Pembroke
Corgis, and English bulldogs comprising 2 enrollees
each. The treatment groups did not differ in any
patient demographic at visit 1 (Table 3). Individual
patient metadata may be found as supplemental
ﬁgure 2. Eight dogs had serum cobalamin concentra-
tions below reference range at enrollment and were
treated for cobalamin deﬁciency using a standard
treatment regimen.24 Ultrasonographic abnormalities
were observed in 8/25 dogs and included mild abdom-
inal effusion (n D 4), loss of normal intestinal wall
layering (n D 3), increased intestinal wall thickness
(n D 8), and/or enlarged and hypoechoic mesenteric
lymph nodes (n D 6), with some dogs having multiple
sonographic abnormalities.
Primary end points
Signiﬁcant differences in the number of colonic total
bacteria (e.g., bacteria summed across all 4 mucosal
compartments) and mucosal bacteria (e.g., bacteria
summed across 3 mucosal compartments including
bacteria found within the mucosa, attached to the sur-
face epithelium, and/or localized within adherent
mucus) as determined by FISH were observed post-
treatment (see supplemental Figs 3A and 3B.). There
were no differences between treatment groups in the
number of total bacteria hybridizing against 5 of the 6
probes at visit 1. Only the total number of Eub338-
positive bacteria were increased in dogs randomized
to receive ST/probiotic (P< 0.02) at enrollment. Simi-
larly, the total number of most bacteria increased sig-
niﬁcantly (P < 0.03 to P < 0.001, depending on the
bacterial group evaluated) regardless of the IBD treat-
ment administered (visit 1 ! visit 3; Fig. 3). Dogs
treated with ST/probiotic showed increased total
numbers of Lactobacillus spp vs. dogs treated with ST
alone (P < 0.001).
Changes in the number of mucosal bacteria mir-
rored those observed for total bacteria except that
Eub338-positive mucosal bacteria failed to increase
(P D 0.13) in dogs treated with ST/probiotic. When
evaluating changes in the spatial distribution of muco-
sal bacteria following IBD therapy, signiﬁcant
increases in bacteria hybridizing to probes against
Eubacteria, Biﬁdobacterium spp, Faecalibacterium
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spp, and Enterobacteriaceae were observed within
adherent mucus of dogs treated with ST; while, these
same bacterial groups and Lactobacillus spp were
increased within the adherent mucus of IBD dogs
receiving ST/probiotic therapy (P < 0.001 for each;
Fig. 4). A comparison of treatment effects involving
adherent mucus bacteria showed that ST therapy pref-
erentially increased mucosal Biﬁdobacteria spp (P <
0.05) while ST/probiotic therapy preferentially
increased mucosal Lactobacillus spp (P < 0.001).
Clinical disease severity (CIBDAI) at enrollment
(visit 1) was scored as moderate-to-severe in both
treatment groups. Similarly, both treatments were
associated with signiﬁcantly reduced CIBDAI scores
at visits 2 and 3 as compared with visit 1 (P < 0.001;
Fig. 5). At visit 2, clinical remission was observed in
12/14 (86%) and 10/12 (83%) of dogs receiving ST/
probiotic and ST therapy, respectively. Only 1 dog in
each treatment group failed to achieve full clinical
remission at visit 3 (e.g., 8 weeks post-treatment).
Since probiotics may affect intestinal barrier integ-
rity, we examined tight junction protein expression
using IHC in intestinal tissues of IBD dogs treated
with ST and ST/probiotics. Probiotic therapy was
associated with upregulated (P < 0.05) expression of
TJPs E-cadherin, occludin, and zonulin when com-
pared with dogs receiving ST (Table 4; Fig. 6).
Correlation between total histopathologic score and
numbers of mucosal bacterial
Total histopathologic scores did not differ pre- vs.
post-treatment in dogs treated with either ST
(P D 0.18) or ST/probiotic (P D 0.08). There was no
association observed between bacterial numbers and
total histopathologic score for either treatment group
(data not shown).
Quantitative PCR analysis performed on feces
Quantitative PCR was used to target select bacterial
groups known to often be altered during health and
disease states. Additionally, qPCR was used to target
speciﬁc genera found in the probiotic cocktail. In the
ST group, Turicibacter, was found to be signiﬁcantly
different (p D 0.0476) when comparing the baseline, 3
week, and 8 week time points. However, post-testing
revealed no signiﬁcant differences between time
points. In the ST/probiotic group, Biﬁdobacterium
was found to be signiﬁcantly increased at 3 weeks
post-treatment compared with baseline (log DNA
Figure 3. FISH of canine IBD endoscopic biopsies. Triple color FISH identiﬁes colonic microbiota within mucosal compartments of endo-
scopic biopsies. Panels A-CD ST/probiotic group and panels D-FD ST group. Panel AD tissue hybridized with probe Cy3-Strc493- Panel
B D tissue hybridized with probe Cy3-Ebac; Panel C D tissue hybridized with probe Cy3-Faecal698; Panel D D tissue hybridized with
probe Cy3-Ebac; Panel E D tissue hybridized with probe Cy3-Bif164; Panel F D issue hybridized with probe Cy3-Strc493. All other bacte-
ria that hybridize exclusively with the universal probe (Eub338-FITC) appear green. DAPI-stained colonic mucosa with goblet cells
appears blue. All images at 600x magniﬁcation. a D attaching bacteria; am D adherent mucus compartment; fm D free mucus
compartment.
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Figure 4. Box plots showing the effect of treatment on the number of colonic microbiota within adherent mucus of IBD dogs treated
with ST or ST/probiotic. Figures A- F show the number of mucosal bacteria which hybridize against each probe: Bif164! Biﬁdobacte-
rium spp, Ebac1790 ! Enterobacteriaceae, Eub338 ! all bacteria, Faecali698 ! Faecalibacterium spp, Lab158 ! Lactobacillus spp,
and Strc493! Streptococcus spp Differences (P < 0.05) in the numbers of bacteria between treatment groups are indicated by the let-
ters A, B, C, and D. Groups with the same letter are not statistically different.
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mean [standard deviation]: 6.8 [0.7] and 4.9 [1.6],
respectively). Statistical analysis also revealed a differ-
ence in the abundance of Lactobacillus in the ST/pro-
biotic group, however, this did not reach statistical
signiﬁcance (P D 0.0665). Supplemental ﬁgures 4
and 5 include graphical representation for all bacterial
groups analyzed by qPCR.
Discussion
There is growing medical evidence in humans that the
consumption of probiotics promotes GI health,
representing a promising new therapy for canine
chronic enteropathies including idiopathic IBD.25-27
Current treatments of canine IBD include the admin-
istration of nonspeciﬁc anti-inﬂammatory drugs (e.g.,
corticosteroids and others) which may confer serious
side effects and do not address the underlying sus-
pected basis for disease, namely, altered microbial
composition. Use of probiotics (viable, non-patho-
genic bacteria that exert health beneﬁts beyond basic
nutrition) offers an attractive, physiologic, and non-
toxic alternative to potentially shift the balance from
harmful to protective bacterial species and treat IBD.
The probiotic product (VisbiomeTM, ExiGi Pharma,
which contains the De Simone Formulation probiotic)
used in the present study contained»1.8£ 1012 live bac-
teria, including L. plantarum DSM24730, L. paracasei
DSM24733, L. delbrueckii subsp bulgaricus DSM24734,
L. acidophilus DSM 24735, S. thermophilus DSM24731,
B. breveDSM24732, B. longumDSM24736, and B. infan-
tisDSM24737. This same probiotic formulation has been
effective in the prevention and treatment of colitis in dif-
ferent rodent models of intestinal inﬂammation,28-30 and
is useful in the management of a subset of human IBD
patients diagnosed with ulcerative colitis31,32 and
pouchitis.33,34 The exact mechanism underlying the ther-
apeutic effect of the probiotic is currently unknown. It
has been hypothesized that the beneﬁcial activities might
include altering the composition of the microbiota by
competition for adhesion sites and nutrients or by secre-
tion of bacteriocins and lactic acids, enhancement
of intestinal barrier function (via increased production of
mucus and anti-microbial peptides by epithelia), and
modulation of immune cell responses.35,36
There are only few reports on the use of probiotic
bacteria in dogs with gastroenteritis. Earlier in vitro
studies have conﬁrmed the ability of a lyophilized
probiotic cocktail (e.g., 3 different Lactobacillus spp
strains) to modulate the expression of regulatory vs.
pro-inﬂammatory cytokines in dogs with chronic
enteropathies.37 However, a clinical trial using this
same probiotic cocktail fed to dogs with food-respon-
sive diarrhea failed to induce consistent patterns of
beneﬁcial cytokine expression in spite of clinical
improvement.38 Still others have reported variable
clinical efﬁcacy of E. faecium strain SF68 in eradicat-
ing giardial cyst shedding, fecal giardial antigen and
immune responsiveness in dogs,39 while it’s use was
associated with shortened time to improved stool
consistency in dogs having acute gastroenteritis.40
Figure 5. Temporal evaluation of clinical (CIBDAI) scores by IBD
treatment group. CIBDAI D canine IBD activity index; ST D stan-
dard therapy; V D visit.
Table 4. Quantiﬁcation of the number of epithelial cells express-
ing select TJPs in the intestinal mucosa of IBD dogs treated with
ST or ST/probiotic. Intestinal biopsies were evaluated before and
after 8 weeks of IBD treatment. Data expressed as the median
number of IHC positive cells/62,500 mm2 of mucosa. Median val-
ues compared between the duodenum and colon before and
after treatment using Wilcoxon rank sum tests.  Indicates signiﬁ-
cant difference (P < 0.05). NP D not performed.
Claudin-2 E-cadherin Occludin Zonulin
Duodenum
Pre-ST/probiotic 1011 827 133 452
Post-ST/probiotic 741 997 947 1125
Pre-ST 782 1017 1098 371
Post-ST 751 1287 1413 117
Colon
Pre-ST/probiotic 1212 575 131 61
Post-ST/probiotic 82 902 859 326
Pre-ST 248 NP NP NP
Post-ST 192 NP NP NP
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Treatment of CE dogs with E. faecium plus a prebi-
otic (FOS) alongside dietary intervention had no
effect on inﬂammasome gene expression in a separate
trial.41
More recently, a multi-strain probiotic was shown
to enhance clinical remission and reduce histopatho-
logic inﬂammation in IBD dogs when administered
continuously for 8 weeks.10 While this earlier study
and the present report were both associated with
robust clinical remission, we were unable to conﬁrm
signiﬁcant histopathologic improvement associated
with probiotic use in the IBD dogs our study. This dif-
ference might be explained by variation in clinical dis-
ease duration and severity and/or differences in the
Figure 6. Tight junction protein (TJP) expression in intestinal epithelia of canine IBD endoscopic biopsies. (Top 2 rows): Panel shows IHC
staining for TJP in colonic biopsies of dogs treated with ST. (Bottom row): Panel shows immunohistochemical (IHC) staining for TJPs in
duodenal biopsies of ST/probiotic treated dogs as compared with H&E (control) tissue. IHC protein expression was deﬁned by the num-
ber of epithelial cells within the mucosa expressing a select TJP. See Table 4 for additional information.
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magnitude of histopathologic inﬂammation observed
at diagnosis in IBD dogs of the present study. More-
over, in contrast to this earlier report, we did not eval-
uate the expression of mucosal TGF-bC or the
number of CD3C T cells and FoxP3C cells in
response to either IBD therapy. Our qPCR results
showed that the abundance of Turicibacter spp (ST
group) and Biﬁdobacterium spp (ST/probiotic group)
in feces were increased in IBD dogs post-treatment
while the earlier trial showed that only the abundance
of Faecalibacterium spp was increased in IBD dogs
receiving combination probiotic. No signiﬁcant
changes were observed for any other bacterial groups
in response to treatment.
In this study, we show now that ST (e.g., elimina-
tion diet and oral prednisone dosed at anti-inﬂamma-
tory levels) and ST C probiotic modulate the number
of mucosal bacteria of dogs with IBD in a similar fash-
ion following 8 weeks of continuous administration.
Moreover, both IBD therapies increased the numbers
of bacterial species residing within the adherent
mucus compartment. Comparison of the effects
between IBD treatments showed that ST therapy sig-
niﬁcantly increased Biﬁdobacterium spp and ST/pro-
biotic therapy signiﬁcantly increased Lactobacillus spp
in the adherent mucus compartment of colonic tissues
vs. the other treatment, respectively. Probiotic therapy
was associated with upregulated expression patterns
of TJPs in duodenal and colonic biopsies suggesting
potential effects of combination probiotic on intestinal
barrier function.42
It is now well established that canine chronic
enteropathies, including IBD, are associated with
broad shifts in the intestinal microbiota which
includes reduced microbial diversity (e.g., reduction
in Firmicutes, class Clostridia including Clostridium
clusters IX and XIV, genus Bacteroides, and Fusobac-
teria with increases in Proteobacteria and Enterobac-
teriaceae).43 These data are derived from separate
investigations where microbial composition was
investigated by culture-independent methods such as
454 pyrosequencing,6 gene clone libraries,8,44,45 and
quantitative PCR techniques.10,46 Direct assessment
of mucosal bacteria using FISH has provided compel-
ling new evidence on the association between altered
composition and spatial organization of intestinal
microbes and disease pathogenesis in dogs with gran-
ulomatous colitis47 and other forms of IBD and colo-
rectal cancer.23 Furthermore, eradication of invasive
E. coli with antibiotic therapy was associated with
histopathologic improvement and resolution of GI
signs, suggesting that interventions targeting harmful
mucosal bacterial species are important treatment
considerations.48
This is the ﬁrst study using FISH methods to local-
ize, quantify, and directly compare different medical
treatments on mucosal bacterial populations in dogs
with IBD. Our experimental design allowed assess-
ment of steroid-induced changes in mucosal micro-
biota which had not been previously reported. The
most important ﬁnding of this study obtained using
FISH was the absence of a signiﬁcant difference in the
numbers of colonic microbiota following treatment of
IBD dogs with ST vs. ST/probiotic. Our results are dif-
ﬁcult to compare with previous studies since only one
other trial has investigated probiotic therapy in IBD
dogs. Here, Rossi et al showed that increased fecal
concentrations of Faecalibacterium spp and Turici-
bacter spp were present in IBD dogs fed a multi-strain
probiotic continuously for 8 weeks.10 Similar to Rossi,
we observed increased luminal concentrations of select
beneﬁcial bacterial species, including Biﬁdobacterium
spp, in the IBD dogs treated with ST/probiotic. Our
results are also consistent with those obtained using
terminal restriction fragment length polymorphism
(T-RFLP) methods to investigate the impact of a pro-
biotic mixture on the mucosal-adherent colonic
microbiota of TNBS-induced colitis in rats.29 In this
trial, probiotic consumption did not signiﬁcantly
affect species richness or biodiversity of the mucosal
microbiota but was associated with decreased severity
of colitis. In contrast, a separate study showed that
multi-strain probiotic therapy could alter luminal and
mucosal microbial composition but did not protect
against colitis-associated inﬂammation and tumori-
genesis in susceptible mice.49
We hypothesized that probiotic effects in IBD dogs
would preserve epithelial barrier function through
increased number of cells expressing TJP as previously
shown in other IBD animal models.10,50,51 As com-
pared with ST, IBD dogs fed probiotic had increased
numbers of cells expressing E-cadherin, occludin, and
zonulin TJPs which suggests that the probiotic may
have beneﬁcial effects on mucosal homeostasis. In
support of this notion, we investigated whether
increased number of cells expressing TJPs would be
associated with histopathologic improvement in dogs
treated with probiotic, similar to an earlier report.10
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Results indicated that while histopathologic scores
improved following probiotic therapy in IBD dogs,
the cumulative mean score approached (P D 0.086)
but did not reach statistical signiﬁcance similar to
dogs treated with ST. One difference between our
study and the early report was that we evaluated tem-
poral changes (visit 1! visit 3) in the number of TJP
expressing cells while Rossi reported treatment-depen-
dent differences in the number of TJP expressing cells
only post-treatment. We now extend these initial
observations to show that the number of cells express-
ing TJP molecule zonulin is increased in the small and
large intestines of IBD dogs treated with combination
probiotic. Our studies have important translational
implications since the spontaneous canine model
shares remarkable homology to human IBD including
known genetic basis, pivotal role for gut bacteria in
disease pathogenesis, similar clinical presentation and
disease activity indices, method of deﬁnitive diagnosis
(biopsy), and positive response to immunosuppressive
therapy.52
There were no major adverse effects reported with
either IBD therapy. Clients whose dogs were random-
ized to receive ST/probiotic reported that the product
was palatable and well tolerated by their pet. As
expected, some large dogs (> 35 kg body weight)
receiving glucocorticoids exhibited transient panting,
polydipsia, and/or polyuria which resolved as predni-
sone dosages were reduced, accordingly.
There are some potential limitations to this study. It
is possible that mucosal bacteria other than those
microbes targeted by our 6 probe array were signiﬁ-
cantly altered as a consequence of ST or ST/probiotic
therapy. All dogs in the trial received routine colonic
cleansing before collection of ileal and colonic muco-
sal biopsies. In these instances, the administration of
oral colonic electrolyte lavage solutions and enemas
might have disrupted mucus compartments and
reduced bacterial populations available for mucosal
counting.53 However, we have previously investigated
bacterial populations by FISH in pilot studies using
untreated colonic specimens and found that mucus
compartments do not differ appreciably between
purged vs. non-purged dogs.23 Another potential fac-
tor impacting quantiﬁcation of mucosal bacteria
might be mechanical artifacts associated with tissue
processing (microtome cutting) and/or non-intended
wash of biopsy specimens by formalin solutions dur-
ing transport to the pathology laboratory.54 Our
previous experiences have allowed us to readily iden-
tify these tissue artifacts and to avoid these areas, if
present, when performing mucosal bacterial counts.
Finally, gut microbial populations may vary by age,
gender, breed, and dietary consumption. Our own
studies, evaluating the potential impact of age, body
weight, and/or diet have not identiﬁed any signiﬁcant
associations of microbial abundances with these varia-
bles in dogs to date.6,46,55
Finally, our trial lacked sufﬁcient power to deﬁni-
tively deﬁne the effect of treatment between dog
groups. Sample size was derived following consulta-
tion with a statistician (n D 32 total dogs over
36 months which included a 20% “washout”) and was
based on initial power calculations using variability in
CIBDAI scores between IBD treatments.11 The num-
ber of dogs (n D 34) initially enrolled in the trial met
this minimum requirement. While the dog population
in total completing the trial failed to reach statistical
power for deﬁnitive conclusion, it is probably likely
that our results regarding the effect of treatment on
mucosal bacterial populations are correct.
In conclusion, this is the ﬁrst study using FISH
methods to localize, quantify, and directly compare dif-
ferent medical treatments on mucosal bacterial popula-
tions in canine IBD. There were no differences in the
numbers of mucosal bacteria following treatment of
IBD dogs with ST vs. probiotic. Changes in mucosal
bacteria in probiotic treated IBD dogs were accompa-
nied by increased number of cells expressing select tight
junction proteins in intestinal tissues. Microbiota from
mucosal samples more clearly represent the underlying
microbial dysbiosis, at diagnosis and in response to
treatment, as compared with fecal samples.
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